IN2014MU01248A - - Google Patents

Info

Publication number
IN2014MU01248A
IN2014MU01248A IN1248MU2014A IN2014MU01248A IN 2014MU01248 A IN2014MU01248 A IN 2014MU01248A IN 1248MU2014 A IN1248MU2014 A IN 1248MU2014A IN 2014MU01248 A IN2014MU01248 A IN 2014MU01248A
Authority
IN
India
Prior art keywords
stabilizer
surfactant
buffer
pharmaceutical composition
relates
Prior art date
Application number
Inventor
Gadgil Himanshu
Chhatbar Chandresh
Pandey Vijaykant
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Priority to CA2944330A priority Critical patent/CA2944330A1/en
Priority to US15/301,421 priority patent/US10688187B2/en
Priority to PCT/IN2015/000092 priority patent/WO2015151115A1/en
Priority to EP15774333.7A priority patent/EP3125928A4/en
Priority to IN1248MU2014 priority patent/IN2014MU01248A/en
Publication of IN2014MU01248A publication Critical patent/IN2014MU01248A/en
Priority to US16/894,196 priority patent/US20200405864A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a liquid pharmaceutical composition comprising an anti-TNFa antibody, buffer, stabilizer, and surfactant.
IN1248MU2014 2014-04-02 2015-02-18 IN2014MU01248A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2944330A CA2944330A1 (en) 2014-04-02 2015-02-18 Liquid pharmaceutical composition of adalimumab
US15/301,421 US10688187B2 (en) 2014-04-02 2015-02-18 Liquid pharmaceutical composition of adalimumab
PCT/IN2015/000092 WO2015151115A1 (en) 2014-04-02 2015-02-18 Liquid pharmaceutical composition of adalimumab
EP15774333.7A EP3125928A4 (en) 2014-04-02 2015-02-18 Liquid pharmaceutical composition of adalimumab
IN1248MU2014 IN2014MU01248A (en) 2014-04-02 2015-02-18
US16/894,196 US20200405864A1 (en) 2014-04-02 2020-06-05 Liquid pharmaceutical composition of adalimumab

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1248MU2014 IN2014MU01248A (en) 2014-04-02 2015-02-18

Publications (1)

Publication Number Publication Date
IN2014MU01248A true IN2014MU01248A (en) 2015-10-09

Family

ID=54239505

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1248MU2014 IN2014MU01248A (en) 2014-04-02 2015-02-18

Country Status (5)

Country Link
US (2) US10688187B2 (en)
EP (1) EP3125928A4 (en)
CA (1) CA2944330A1 (en)
IN (1) IN2014MU01248A (en)
WO (1) WO2015151115A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426833B2 (en) 2014-05-23 2019-10-01 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US10426832B2 (en) 2014-05-23 2019-10-01 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US10493152B2 (en) 2014-05-23 2019-12-03 Fresenius Kabi Deutschland Gmbh Adalimumab formulations

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180599A (en) * 2016-06-30 2019-04-09 Celltrion Inc STABLE LIQUID PHARMACEUTICAL PREPARATION
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN120392659A (en) 2017-01-11 2025-08-01 赛特瑞恩股份有限公司 Stable liquid formulations
MX2019010895A (en) * 2017-03-16 2019-11-05 Lg Chemical Ltd Liquid formulation of anti-tnf alpha antibody.
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
JP2022525556A (en) * 2019-03-18 2022-05-17 アルヴォテック エイチエフ High-concentration aqueous formulation of TNF-alpha antibody
AU2020358101A1 (en) * 2019-10-02 2022-04-28 Alamab Therapeutics, Inc. Anto-connexin antibody formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE122004000004I1 (en) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Human antibodies that bind to human TNFalpha.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
PL215168B1 (en) 2002-02-27 2013-10-31 Immunex Corp Polypeptide formulation
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
AU2011325974B2 (en) * 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
CN104023748B (en) 2011-10-28 2018-03-02 诚信生物公司 Protein Preparations Containing Amino Acids
JP2015509526A (en) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド Pharmaceutical formulation
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
AU2013312300A1 (en) * 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
HUE029849T2 (en) * 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
EP3250598A1 (en) 2015-01-28 2017-12-06 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426833B2 (en) 2014-05-23 2019-10-01 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US10426832B2 (en) 2014-05-23 2019-10-01 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US10493152B2 (en) 2014-05-23 2019-12-03 Fresenius Kabi Deutschland Gmbh Adalimumab formulations
US10729769B2 (en) 2014-05-23 2020-08-04 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US10772961B2 (en) 2014-05-23 2020-09-15 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US11707524B2 (en) 2014-05-23 2023-07-25 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US11712471B2 (en) 2014-05-23 2023-08-01 Fresenius Kabi Deustschland GmbH Liquid pharmaceutical composition
US11752209B2 (en) 2014-05-23 2023-09-12 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US11752208B2 (en) 2014-05-23 2023-09-12 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
US12109267B2 (en) 2014-05-23 2024-10-08 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition

Also Published As

Publication number Publication date
US20170106090A1 (en) 2017-04-20
WO2015151115A1 (en) 2015-10-08
US10688187B2 (en) 2020-06-23
US20200405864A1 (en) 2020-12-31
CA2944330A1 (en) 2015-10-08
EP3125928A1 (en) 2017-02-08
EP3125928A4 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical compositions and uses thereof
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
IN2014MU01248A (en)
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
ZA201701168B (en) Antibodies, compositions, and uses
IL255443B (en) Anti-cgrp antibody formulation
MX2020009649A (en) Monoclonal antibodies against bcma.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
SG10201803042PA (en) Anti-tim-3 antibodies
CL2016002772A1 (en) Fast-acting insulin compositions
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2019007021A (en) Il-11ra antibodies.
PH12016501763B1 (en) Multispecific antibodies
MY191581A (en) Anti-pd-1 antibodies
MX2020005213A (en) Mk2 inhibitors and uses thereof.
IL257956A (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
MY181175A (en) Therapeutic hpv16 vaccines
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
IL247100A0 (en) Anti cd84 antibodies, compositions comprising same and uses thereof
IL237852A0 (en) Anti amphiregulin antibodies, compositions comprising same and uses thereof
CL2015002896S1 (en) Perfume bottle.
RU2015118269A (en) Universal bottle
UA99992U (en) 2,34-tetrahydropyridin-6-thiolate
TN2014000522A1 (en) لوح مدرسي بوجهين